Filana Therapeutics receives Nasdaq notice for sub-$1 minimum bid price noncompliance

• Nasdaq flagged Filana Therapeutics for noncompliance with the $1 minimum bid-price rule after 30 straight business days below $1.
• Shares keep trading on the Nasdaq Capital Market under FLNA while the company gets 180 days, until March 16, 2027, to regain compliance.
• Compliance requires a closing bid price of at least $1 for 10 consecutive business days during the cure period.
• Failure to cure could trigger a delisting determination, with a possible appeal to a Nasdaq hearings panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-030751), on September 18, 2026, and is solely responsible for the information contained therein.